Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Celgene : Scripps hopes for royalty windfall from potential blockbuster drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/11/2017 | 12:54am CEST

Nov. 10--If the new drug ozanimod achieves blockbuster status, it could generate tens of millions of dollars a year in royalties for the Scripps Research Institute -- and provide relief from the ongoing financial challenges facing the nonprofit lab.

Scripps won't say how much it stands to receive from sales of ozanimod, a drug that slows brain atrophy in patients with multiple sclerosis. Scripps discovered the drug, then partnered with Celgene to shepherd the medicine through clinical trials. The biopharmaceutical company expects to begin marketing the drug to MS patients in late 2018.

Celgene (Nasdaq: CELG) also is testing ozanimod as a treatment for ulcerative colitis, which is more common than MS. If ozanimod wins approval as a medicine for the intestinal disorder, sales could reach $4 billion to $6 billion a year.

Scripps says its royalty arrangement with Celgene is confidential. Brian Skorney, an analyst who follows Celgene for Robert W. Baird & Co., said the typical deal pays a drug's inventor "in the low single-digit percentage."

So, if ozanimod's sales reach $4 billion and Scripps gets a 2 percent cut, that would amount to $80 million a year. It would be a welcome windfall for Scripps, which has seen its revenue decline steadily in recent years.

The nonprofit lab's revenue fell to $347.5 million for the year ended Sept. 30, 2016, according to a financial statement, down from $362.5 million the previous year.

It was the fifth consecutive year of declining revenue for San Diego-based Scripps, the scientific juggernaut that's the anchor of Florida's billion-dollar bet on biotech. Scripps in 2016 reported its lowest annual revenue since 2004.

Scripps' net assets dipped to $637 million, down from $647 million in 2015 and the lowest level since 2007.

Dr. Hugh Rosen, a Scripps researcher who's the co-inventor of ozanimod, said the institute's agreement with Celgene calls for royalty payments through 2033 or 2034.

"It could be a significant contributor to the health of the institution," Rosen said.

Patient studies proved that ozanimod is safe and effective, but it's still no sure thing. Skorney said ozanimod faces competition from other MS drugs.

"It's a very crowded space in terms of the number of effective treatments, so we'll see how Celgene ends up pricing it," Skorney said.

Rosen said ozanimod's journey from the lab to the doctor's office underscores the long-term nature of scientific research. In 2002, he started the work that led to ozanimod, and a flurry of tests from 2006 to 2008 ultimately yielded the new drug.

"It will be literally 10 years from discovery to launch for patients, and that's about as fast as you could hope for," Rosen said.

___

(c)2017 The Palm Beach Post (West Palm Beach, Fla.)

Visit The Palm Beach Post (West Palm Beach, Fla.) at www.palmbeachpost.com

Distributed by Tribune Content Agency, LLC.

© Tribune Content Agency, source Regional News

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
07:30pCELGENE : New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsi..
AQ
10:56aZYMEWORKS : and Celgene Expand Bispecific Antibody Collaboration
AQ
10:20aCELGENE : Longtime Juno Therapeutics CEO Hans Bishop leaves role after acquisiti..
AQ
04/25CELGENE CORPORATION : Announces Changes to Its Board of Directors
AQ
04/24CELGENE : New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsi..
BU
04/21CELGENE SHAREHOLDER ALERT BY FORMER : Kahn Swick & Foti, LLC Reminds Investors ..
BU
04/20Levi & Korsinsky, LLP Notifies Shareholders of Celgene Corporation of Commenc..
BU
04/20CELGENE CORPORATION : SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Rem..
AC
04/20CELGENE CORPORATION : to Webcast at Upcoming Investor Conferences
AQ
04/19BRAGAR EAGEL & SQUIRE, P.C. : Reminds Investors That a Class Action Lawsuit Has ..
BU
More news
News from SeekingAlpha
08:30aWe Believe Janssen Has Separated From Geron. Just Awaiting Divorce Papers 
04/25PROTHENA : A Compelling Bounce Play To At Least $15 And Not Unrealistic Buyout T.. 
04/25AbbVie files U.S. marketing application for plaque psoriasis med risankizumab 
04/24Prothena Ends Up With Two Trial Failures, Becomes A Great Short Opportunity 
04/24BY THE NUMBERS : Healthcare Stocks With Big Cash Distributions 
Financials ($)
Sales 2018 14 809 M
EBIT 2018 8 492 M
Net income 2018 5 310 M
Debt 2018 3 897 M
Yield 2018 -
P/E ratio 2018 13,05
P/E ratio 2019 10,85
EV / Sales 2018 4,79x
EV / Sales 2019 3,65x
Capitalization 67 049 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 116 $
Spread / Average Target 30%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
Peter N. Kellogg Executive VP, Chief Financial & Accounting Officer
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Rupert J. Vessey President-Research & Early Development
Gilla Kaplan Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-14.58%67 049
JOHNSON & JOHNSON-9.68%338 522
PFIZER2.32%220 455
NOVARTIS-8.69%202 567
ROCHE HOLDING LTD.-11.66%193 904
MERCK AND COMPANY5.97%161 967